ACULAR LS Rx
Generic Name and Formulations:
Ketorolac tromethamine 0.4%; oph soln; contains benzalkonium chloride.
Indications for ACULAR LS:
Ocular pain and burning/stinging after corneal refractive surgery.
Adults and Children:
<3yrs: not established. ≥3yrs: 1 drop 4 times daily as needed for up to 4 days post-op.
Do not administer while wearing contacts. Bleeding tendencies. Complicated or repeat ocular surgeries. Corneal defects/denervation. Ocular surface diseases. Diabetes. Rheumatoid arthritis. May delay wound healing. Monitor cornea; discontinue if corneal epithelial breakdown occurs. Hypersensitivity to aspirin. History of asthma. Pregnancy (Cat.C): avoid in late pregnancy. Nursing mothers.
May potentiate oral anticoagulants.
Transient stinging, burning, conjunctival hyperemia, corneal infiltrates, headache, ocular edema, ocular pain/inflammation/irritation, superficial keratitis or infections, allergic reactions, increased ocular bleeding (including hyphemas).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma